Slow Take Off For Taiwan’s Fast-Track NDA Program
This article was originally published in PharmAsia News
Taiwan’s new fast-track NDA process is expected to reduce review time from 360 days to 200, or even less for three categories of drugs.
You may also be interested in...
China and Taiwan's top health regulators have signed an agreement to harmonize clinical and non-clinical studies toward mutual data acceptance. The deal could open doors for more Taiwanese drugs in the Chinese market, industry experts say
Regulators from Japan and Taiwan met in late December to review prospects for convergence and pointed to manufacturing and new drug approvals as areas that were ripe for harmonization agreements.
Following an agreement by six multinational firms – including GlaxoSmithKline and AbbVie – to cut prices for antiretrovirals, Taiwan’s Centers for Disease Control is looking to import generic drugs for its free HIV drug reimbursement program, which has met with success only to see costs explode.